Bruton’s Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Bruton’s Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Bruton’s Tyrosine Kinase (BTK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Overview
Bruton's tyrosine kinase (Bruton’s agammaglobulinemia tyrosine kinase; BTK) is a nonreceptor, cytoplasmic tyrosine kinase which plays an important role in B-lymphocyte development, differentiation, and signaling. It is a member of the Tec family of kinases which is involved in regulating the B cell proliferation. Btk also has a role in Toll-like receptor and FcR signaling in myeloid cells. Bruton’s tyrosine kinase (BTK) inhibitors work by binding to the BTK protein. BTK inhibitors block this protein’s activity by the BCR-induced BTK activation and its downstream signalling.
Function - BTK is predominantly expressed in B lymphocytes but not in plasma cells. BTK expression in the B-cell lineage is also developmentally regulated, with marrow-derived hematopoietic stem cells, common lymphoid progenitor cells, developing B and myeloid lineages showing the highest levels, whereas resting mature cells prior to activation have reduced cellular BTK. BTK is expressed in many hematopoietic cell types, where its involvement in various pathways has been defined. Likewise, in B cells, BTK participates in multiple pathways, including chemokine receptor and TLR signaling.
Bruton’s Tyrosine Kinase (BTK) Inhibitors - Targeting of BTK, which has a central role in several signaling pathways in B cells, particularly the BCR, has shown impressive efficacy as therapeutic option for various B cell malignancies in clinical trials. Much progress has been made in recent years in defining the complex mechanisms of action of BTK inhibition. These involve intrinsic signaling pathways in leukemic cells that are central to cellular survival, proliferation and - most importantly - retention in supportive microenvironments. Moreover, BTK inhibition shows promise as a therapy that influences crucial immune cells in the tumor microenvironment. Because data from BTK-deficient or inhibitor-treated myeloid cells in the context of cancer are scarce, it is not clear whether BTK inhibition by e.g. ibrutinib is based on its specificity for BTK in particular myeloid cells and/or due to off-target effects in signaling pathways in CD4+ or CD8+ T cells.
Bruton’s Tyrosine Kinase (BTK) Inhibitor Emerging Drugs Chapters
This segment of the Bruton’s Tyrosine Kinase (BTK) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bruton’s Tyrosine Kinase (BTK) Inhibitor Emerging Drugs
Further product details are provided in the report……..
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bruton’s Tyrosine Kinase (BTK) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Bruton’s Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Bruton’s Tyrosine Kinase (BTK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Overview
Bruton's tyrosine kinase (Bruton’s agammaglobulinemia tyrosine kinase; BTK) is a nonreceptor, cytoplasmic tyrosine kinase which plays an important role in B-lymphocyte development, differentiation, and signaling. It is a member of the Tec family of kinases which is involved in regulating the B cell proliferation. Btk also has a role in Toll-like receptor and FcR signaling in myeloid cells. Bruton’s tyrosine kinase (BTK) inhibitors work by binding to the BTK protein. BTK inhibitors block this protein’s activity by the BCR-induced BTK activation and its downstream signalling.
Function - BTK is predominantly expressed in B lymphocytes but not in plasma cells. BTK expression in the B-cell lineage is also developmentally regulated, with marrow-derived hematopoietic stem cells, common lymphoid progenitor cells, developing B and myeloid lineages showing the highest levels, whereas resting mature cells prior to activation have reduced cellular BTK. BTK is expressed in many hematopoietic cell types, where its involvement in various pathways has been defined. Likewise, in B cells, BTK participates in multiple pathways, including chemokine receptor and TLR signaling.
Bruton’s Tyrosine Kinase (BTK) Inhibitors - Targeting of BTK, which has a central role in several signaling pathways in B cells, particularly the BCR, has shown impressive efficacy as therapeutic option for various B cell malignancies in clinical trials. Much progress has been made in recent years in defining the complex mechanisms of action of BTK inhibition. These involve intrinsic signaling pathways in leukemic cells that are central to cellular survival, proliferation and - most importantly - retention in supportive microenvironments. Moreover, BTK inhibition shows promise as a therapy that influences crucial immune cells in the tumor microenvironment. Because data from BTK-deficient or inhibitor-treated myeloid cells in the context of cancer are scarce, it is not clear whether BTK inhibition by e.g. ibrutinib is based on its specificity for BTK in particular myeloid cells and/or due to off-target effects in signaling pathways in CD4+ or CD8+ T cells.
Bruton’s Tyrosine Kinase (BTK) Inhibitor Emerging Drugs Chapters
This segment of the Bruton’s Tyrosine Kinase (BTK) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bruton’s Tyrosine Kinase (BTK) Inhibitor Emerging Drugs
- Tolebrutinib: Sanofi
- Evobrutinib: Merck
- ICP-022: Beijing InnoCare Pharma Tech
- LOU064: Novartis
- TG 1701: TG therapeutics
Further product details are provided in the report……..
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Bruton’s Tyrosine Kinase (BTK) Inhibitor
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Topical.
- Molecule Type
- Small molecule
- Skin disorder therapy
- Anti-inflammatory
- Antineoplastic
- Antirheumatics
- Product Type
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bruton’s Tyrosine Kinase (BTK) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Bruton’s Tyrosine Kinase (BTK) Inhibitor R&D. The therapies under development are focused on novel approaches for Bruton’s Tyrosine Kinase (BTK) Inhibitor.
- Bruton’s Tyrosine Kinase (BTK) Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs?
- How many Bruton’s Tyrosine Kinase (BTK) Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Bruton’s Tyrosine Kinase (BTK) Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bruton’s Tyrosine Kinase (BTK) Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bruton’s Tyrosine Kinase (BTK) Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sanofi
- Merck
- Beijing InnoCare Pharma Tech
- Hoffman-La-Roche
- BeiGene
- Principia Biopharma
- Janssen
- AstraZeneca
- Sorrento Therapeutics
- Novartis
- Zhejiang DTRM Biopharma
- Merck Sharp & Dohme
- TG therapeutics
- AbbVie
- Telios Pharma
- Taiho Pharmaceutical
- Gilead Sciences
- Aptose Biosciences
- Sinomab
- Nurix
- Biogen
- Carna Biosciences
- Eli Lilly and Company
- Tolebrutinib
- Evobrutinib
- ICP-022
- RG7845
- Zanubrutinib
- PRN-1008
- Imbruvica
- Acalabrutinib
- Abivertinib
- LOU064
- DTRM-555
- MK-1026
- TG-1701
- ABBV-599
- TL 895
- TAS 5315
- Tirabrutinib
- Luxeptinib
- SN1011
- NX-2127
- BIIB091
- AS-0871
Introduction
Executive Summary
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bruton’s Tyrosine Kinase (BTK) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bruton’s Tyrosine Kinase (BTK) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bruton’s Tyrosine Kinase (BTK) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tolebrutinib: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LOU064: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SN1011: Sinomab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
KBP-7536: KBP Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Companies
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Products
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Unmet Needs
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Market Drivers and Barriers
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Future Perspectives and Conclusion
Bruton’s Tyrosine Kinase (BTK) Inhibitor Analyst Views
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Companies
Appendix
Executive Summary
Bruton’s Tyrosine Kinase (BTK) Inhibitor: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bruton’s Tyrosine Kinase (BTK) Inhibitor – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bruton’s Tyrosine Kinase (BTK) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bruton’s Tyrosine Kinase (BTK) Inhibitor Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tolebrutinib: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LOU064: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SN1011: Sinomab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
KBP-7536: KBP Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Companies
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Products
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Unmet Needs
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Market Drivers and Barriers
Bruton’s Tyrosine Kinase (BTK) Inhibitor- Future Perspectives and Conclusion
Bruton’s Tyrosine Kinase (BTK) Inhibitor Analyst Views
Bruton’s Tyrosine Kinase (BTK) Inhibitor Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Bruton’s Tyrosine Kinase (BTK) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Bruton’s Tyrosine Kinase (BTK) Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Bruton’s Tyrosine Kinase (BTK) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Bruton’s Tyrosine Kinase (BTK) Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products